Agenus joined oncology leaders from across the globe at ASCO GI (GI24)

Agenus recently posted on their LinkedIn page:

“Agenus joined oncology leaders from across the globe at ASCO GI (GI24). We are proud to partner with Pashtoon Kasi from Weill Cornell Medicine who presented data from the NEST-1 trial of neoadjuvant botensilimab plus balstilimab in resectable mismatch repair proficient and deficient colorectal cancer. The findings underscore the potential to help patients in earlier stages of colorectal cancer.

Learn more about the data by reading our press release and visit the publications section of our website to view the poster.”

Source: Agenus/LinkedIn